'Osmosin' in rheumatoid arthritis: interim results.
The interim results of an on-going trial in patients with active rheumatoid arthritis are reported. The findings from 17 patients so far treated and followed-up for 4 to 6 weeks suggest that 'Osmosin' (105 mg sodium indomethacin trihydrate), given once daily for the first 2 weeks and twice daily thereafter, is effective in reducing the inflammatory activity of joint disease, as assessed by visual analogue and 5-point semantic severity scales. Analysis showed that there was a strong association between the assessments on the two scales and this was stronger if patients were not conditioned by being allowed to see their previous visual analogue scale assessment.